A Novel Approach to Determining Violence Risk in Schizophrenia: Developing a Stepped Strategy in 13,806 Discharged Patients by Singh, Jay P. et al.
A Novel Approach to Determining Violence Risk in
Schizophrenia: Developing a Stepped Strategy in 13,806
Discharged Patients
Jay P. Singh
1, Martin Grann
2, Paul Lichtenstein
3, Niklas La ˚ngstro ¨m
2, Seena Fazel
1*
1Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom, 2Centre for Violence Prevention, Karolinska Institutet, Stockholm, Sweden,
3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Abstract
Clinical guidelines recommend that violence risk be assessed in schizophrenia. Current approaches are resource-intensive as
they employ detailed clinical assessments of dangerousness for most patients. An alternative approach would be to first
screen out patients at very low risk of future violence prior to more costly and time-consuming assessments. In order to
implement such a stepped strategy, we developed a simple tool to screen out individuals with schizophrenia at very low risk
of violent offending. We merged high quality Swedish national registers containing information on psychiatric diagnoses,
socio-demographic factors, and violent crime. A cohort of 13,806 individuals with hospital discharge diagnoses of
schizophrenia was identified and followed for up to 33 years for violent crime. Cox regression was used to determine risk
factors for violent crime and construct the screening tool, the predictive validity of which was measured using four outcome
statistics. The instrument was calibrated on 6,903 participants and cross-validated using three independent replication
samples of 2,301 participants each. Regression analyses resulted in a tool composed of five items: male sex, previous
criminal conviction, young age at assessment, comorbid alcohol abuse, and comorbid drug abuse. At 5 years after
discharge, the instrument had a negative predictive value of 0.99 (95% CI=0.98–0.99), meaning that very few individuals
who the tool screened out (n=2,359 out of original sample of 6,903) were subsequently convicted of a violent offence.
Screening out patients who are at very low risk of violence prior to more detailed clinical assessment may assist the risk
assessment process in schizophrenia.
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Introduction
Although schizophrenia is consistently associated with an
increased risk of violence compared with general population
controls in different countries and using various definitions of
violence, most individuals with schizophrenia are not dangerous
[1,2]. A recent population study estimated rates of violent crime to
be approximately 10–15% after diagnosis [1], and cohort studies
have reported rates between 8–14% [3–6]. Despite this, current
treatment guidelines in the US and UK recommend that violence
risk be assessed for all individuals diagnosed with schizophrenia
[7,8], and over 100 instruments have been developed to assist in
the prediction of such behaviour in general and psychiatric
populations [9,10]. Available instruments focus on identifying
those patients with schizophrenia who are at highest risk of
violence and typically require several hours to administer, placing
a considerable burden on the resources of mental health services
[11,12].
One approach that could improve the risk assessment process is
to develop instruments to screen out patients who are at very low
risk of future violence that can be used prior to in-depth
assessments of dangerousness (in contrast to current one-step
methods that administer costly risk assessments to all patients
without initial screening). This stepped approach is similar to that
used by many diagnostic screening tools in physical medicine, such
as the use of mammography or prostatic specific antigen screening
for breast or prostate cancer, respectively, prior to biopsy [13], and
allows for clinical resources, including more detailed clinical risk
assessment, to be targeted at those more likely to need
intervention. In addition, using such an approach would assist in
risk management by identifying individuals who could be targeted
for treatment in those who are not screened out.
The objective of the present study was to develop a screening
tool to identify individuals with schizophrenia who are at very low
risk of violence after hospital discharge. We developed and cross-
validated the instrument using a cohort of 13,806 discharged
patients with schizophrenia, with a potential follow-up of 33 years.
Rather than simply turning risk assessment on its head (i.e.,
substituting factors such as previous criminal conviction with no
previous conviction), the tool was statistically developed to
maximise sensitivity (i.e. identifying all those individuals not at
very low risk) for use as part of a stepped strategy. We aimed to
create a tool composed of routinely available factors that was
potentially scalable as it does not require specific training or
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31727additional costs. These properties have been identified as
important for any instrument aiming to be clinically relevant [14].
Methods
Study protocol
The Standards for Reporting of Diagnostic Accuracy Studies
(STARD) Statement [15], a 25-item checklist of reporting
characteristics, was followed.
Data registries
Data was collected from the following nationwide population-
based registers in Sweden: The Hospital Discharge Register
(HDR; held at the National Board of Health and Welfare), the
Migration Register (Statistics Sweden), the Cause of Death
Register (National Board of Health and Welfare), the National
Crime Register (National Council for Crime Prevention),
Education Registers (Statistics Sweden), and the Multi-Generation
Register (Statistics Sweden). Merging these datasets was possible as
all national registers use residents’ (including immigrants) same 10-
digit personal identification numbers. An independent government
organisation (Statistics Sweden) merged the registers and, upon
assigning each participant a novel case number, destroyed the
coding sheet that linked case numbers and personal identification
numbers. This anonymisation made informed consent unneces-
sary. The Ethics Committee at the Karolinska Institutet approved
this protocol (2005/174/31/4).
Participants
Using the HDR, all individuals aged 15 years (the age of
criminal responsibility) and older who had been admitted to
hospital for assessment and/or treatment in Sweden and had been
discharged between January 1, 1973 and December 31, 2004 with
a diagnosis of schizophrenia were identified. The HDR is a high
quality register with less than 1% of hospital discharges missing
personal identification numbers [16]. Diagnoses of schizophrenia
were made using the International Classification of Diseases (ICD-8:
295; ICD-9: 295; ICD-10: F20). Only those individuals who had
been diagnosed with schizophrenia on at least two occasions
(N=13,806) were included to improve specificity [17].
Participants were followed until their first conviction or until
they were censored due to emigration (data obtained from the
Migration Register), death (data obtained from the Cause of Death
Register), or the end of the follow-up period (December 31, 2004).
Calibration and cross-validation samples
The population cohort was randomly divided into two samples
of 6,903 participants. One of the samples was used to develop the
screening tool and the other to cross-validate it. As the use of
regression to develop risk instruments has been criticised for
exaggerating predictive validity estimates in calibration samples
[18,19], the cross-validation sample was randomly split into three
independent subsamples, each consisting of 2,301 participants.
Cross-validating the tool using these subsamples provided the
opportunity to assess shrinkage effects.
Definition of violence
Violent conviction data was extracted from the National Crime
Register for the years 1973–2004. The National Crime Register is
a high quality register, missing only 0.05% of personal
identification numbers between 1988–2000 [16]. Violent crime
was defined as having received a conviction for homicide, assault,
robbery, arson, any sexual offence, illegal threats, or intimidation.
The inclusion of noncontact offences in the operational definition
of violence is consistent with previous risk assessment research
[20,21], including studies that have specifically investigated the
association between schizophrenia and criminal behaviour [1].
Nonviolent offences such as fraud and perjury were not included,
as they were perceived to be of less clinical interest than more
serious behavioural outcomes and as they are not referenced in
current treatment guidelines for schizophrenia [7,8]. Participants
were coded as either having or not having a conviction for a
violent crime during follow-up. Conviction data accurately reflects
resolved criminality in this population as plea-bargaining is not
permitted in Sweden and as individuals are convicted as guilty
regardless of mental illness.
Outcome measures
Four outcome statistics were used to measure predictive validity:
negative predictive value (NPV), positive predictive value (PPV),
diagnostic odds ratio (DOR), and area under the curve (AUC).
These statistics are commonly used outcome measures in the
medical diagnostic literature [22].
The NPV is the proportion of individuals who are predicted by
a tool not to offend who do not offend, whereas the PPV
represents the proportion of individuals who are predicted to
offend who actually offend. Both statistics are base rate dependent.
As the ability to accurately classify individuals as being at risk of
violence in psychiatric populations is highly dependent upon base
rate [23], this may be considered a strength.
The DOR is the ratio of the odds of a true positive relative to
the odds of a false positive. In addition to being independent of the
base rate of offending, the DOR is also useful in that researchers
and clinicians are familiar with the concept of an odds ratio,
making the statistic easier to comprehend for non-specialists [24].
The receiver operating characteristic (ROC) curve plots an
instrument’s true positive rate against its false positive rate across
score thresholds. The area under this curve (AUC) is the
probability that a randomly selected offender has a higher test
score than a randomly selected non-offender [25]. The statistic can
be considered an index of how well a tool discriminates between
offenders and non-offenders. As with the DOR, the AUC is not
base rate dependent.
Risk factors
We prioritised the inclusion of risk factors that could be scored
using routinely collected and accessible file information. These
variables included male sex [26,27], previous criminal conviction
[27], age at assessment [27], comorbid alcohol abuse [28], and
comorbid drug (non-alcohol) abuse [28].
Information on sex was extracted from the HDR. Previous
criminal conviction referred to any crime (violent or not) before
hospital discharge, and was gathered from the National Crime
Register. The age at which participants were discharged from
hospital with a second diagnosis of schizophrenia ranged from 15
to 54 years (Median=26; Interquartile Range=22–33). We used the
Chi-squared Automatic Interaction Detector (CHAID) method
adjusted by time at risk to identify the age cut-off which best
classified participants as being at risk of violent conviction [29].
Data on participants’ hospital admissions during the years 1973–
2004 were extracted from the HDR and examined for evidence of
principal or comorbid diagnoses of alcohol abuse (ICD-8: 303;
ICD-9: 303, 305.1; ICD-10: F10, except 6.5) and drug abuse
(ICD-8: 304; ICD-9: 304, 305.9; ICD-10: F11-F19, except 6.5).
This information was used as a marker of substance abuse
comorbidity. A sensitivity analysis was also conducted for the
following illicit drug categories: opiate, sedative, stimulant,
hallucinogen, and polysubstance abuse.
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[30], having a parent who was convicted of a violent offence [31],
and having a parent who was diagnosed with alcohol abuse [32].
These were considered secondary, as such information may not be
routinely available. One study estimated that school records were
utilized in approximately 15% of clinicians conducting risk
assessments in adults [33]. Participants’ highest level of completed
education was collated from the Education Registers and a binary
comparison was made between those who had completed
compulsory school (a nine year comprehensive school for children
aged 7 to 16) and those who had not.
We linked parents to the National Crime Register using the
Multi-Generational Register to extract data on whether individ-
uals had a father or mother who had previously been convicted of
a violent crime. In addition, parents were linked to the HDR to
extract data on diagnoses of alcohol abuse.
Developing the screening tool
Analyses took place in two stages: in the first stage, the routinely
accessible variables were combined into a five-item unit scored
model (i.e.,a modelwherethepresenceofariskfactorisscored as+1
and the absence as +0) and regressed with violent conviction as the
dependent variable using Cox’s proportional-hazards method [34].
The rates of true positives (TP), false positives (FP), true negatives
(TN),and false negatives(FN)werecalculatedfortheresulting toolat
each risk score at 1, 2, and 5 years follow-up. Participants who were
not at risk for 1, 2, or 5 years (respectively) due to emigration, death,
or end of follow-up were excluded from these calculations.
When selecting a cut-off score, the relative costs of false
negatives and false positives were taken into consideration. The
societal and political costs associated with screening out a patient
who would go on to commit a violent crime were considered to
outweigh the costs associated with conducting more detailed risk
assessments for patients who would not go on to commit a violent
offence. Therefore, the ideal cut-off point was identified as the risk
score that maximised sensitivity while balancing specificity. Using
this cut-off, the instrument’s NPV, PPV, and DOR were
calculated at each length of follow-up, as was AUC using receiver
operating characteristic analysis.
In the second stage, each secondary variable was regressed with
violent conviction as the dependent variable and ranked in order
of their resulting hazard ratios. Variables were added one at a time
to the primary model and, provided the added factor indepen-
dently accounted for variation in the dependent variable, the
revised tool’s predictive validity was assessed at 1, 2, and 5 years
follow-up. Effect estimates were compared with those produced by
the five-item model at the same length of follow-up using 95%
confidence intervals (CI). Additional comparisons were made
using the x
2 test of differences between proportions, Breslow and
Day’s x
2 test of homogeneity between odds ratios [35], and Hanley
and McNeil’s z test for differences in AUC [36]. This process was
repeated for each additive iteration.
Cross-validation
The version of the screening tool that produced the highest rates
of predictive validity using the fewest number of items was then
cross-validated using the three replication subsamples. The effect
estimates produced by the tool in each independent subsample at
1, 2, and 5 years follow-up were compared with those produced by
the calibration sample at the same length of follow-up to examine
evidence of shrinkage.
Analyses were conducted using SPSS 17.0.1 for Windows [37],
STATA/IC 10.1 for Windows [38], and MedCalc 11.3.8.0 for
Windows [39].
Results
Description of the samples
The population cohort consisted of 13,806 individuals with two
or more hospital discharge diagnoses of schizophrenia during
January 1, 1973 and December 31, 2004 (Table 1). The cohort
was randomly divided into a calibration sample (n=6,903) and
three independent cross-validation subsamples (n=2,301 for each).
Calibrating the screening tool
Using the CHAID method, we identified 32 years as the age
cut-off that best classified participants as being at risk of violent
conviction for the ‘‘young age at assessment’’ variable.
Cox regression found that the five routinely accessible factors
(i.e., male sex, previous criminal conviction, young age at
assessment, comorbid alcohol abuse, and comorbid drug abuse)
were significant independent predictors of the incidence of violent
conviction (Table 1).
The TP, FP, TN, and FN rates were calculated for the five-item
tool at each risk score at 1, 2, and 5 years follow-up. The optimal
cut-off score was identified as +2 (Table 2). Of the 2,359
participants who scored below this threshold, 2,353 were not
convicted of a violent offence within 1 year after hospital discharge
(NPV=0.99; 95% CI=0.99–1.00). The screening tool’s PPV at 1
year after discharge was 0.01 (95% CI=0.01–0.02), the DOR was
3.79 (95% CI=1.65–8.72), and the AUC was 0.67 (95%
CI=0.66–0.68). There was a trend towards PPVs, DORs, and
AUCs increasing over 2 and 5 years follow-up, while NPVs
remained at 99% (Table 3). To investigate the instrument’s
performance with different base rates, we measured PPVs and
NPVs at 1, 2, and 5 years follow-up at base rates of 0%, 2%, 4%,
6%, 8%, and 10% (Table 4). While PPVs increased markedly with
increasing base rates, NPVs remained above 95%.
Univariate analyses also found that a number of secondary
variables were significantly associated with the incidence of violent
conviction (Table 1). However, we found no evidence of increased
predictive validity when low level of education, parental conviction for
a violent offence, or parental alcohol abuse comorbidity were added
as items (results not shown). In addition, in a sensitivity analysis, no
evidence of incremental predictive validity was found if one of opiate,
sedative, stimulant, hallucinogen, or polysubstance abuse was
included on the simple screening tool instead of any drug abuse.
Cross-validation
Statistical tests revealed no significant differences between the
effect estimates produced by the five-item instrument in the
calibration and cross-validation samples at each length of follow-
up, suggesting no clear shrinkage effects (Table 3). Of the 2,288
participants in the replication samples who were classified as low
risk, 2,280 did not go on to be convicted of a violent offence within
1 year of hospital discharge (NPV=0.99; 95% CI=0.99–1.00).
Similar to the calibration sample, there was a trend towards PPVs,
DORs, and AUCs increasing over time, while NPVs remained at
or above 98% at 2 and 5 years of follow-up (Table 3).
Discussion
Using data collected from Swedish national registers over three
decades, we investigated violence risk in 13,806 patients with
schizophrenia in order to develop a simple screening tool that could
accurately identify individuals who would not beconvicted of a violent
offence after hospital discharge. The instrument was composed of five
routinely available risk factors: male sex, previous criminal conviction,
young age at assessment, comorbid alcohol abuse, and comorbid drug
Screening for Violence Risk in Schizophrenia
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out’’ decisions (i.e., identifying who will not go on to violently offend),
suggesting potential utility as a screening tool that could be used as
part of a stepped approach to risk assessment. In this approach, very
low risk patients are screened out, allowing for more detailed and
resource-intensive assessment and management on the remaining (or
screen positive) patients. The reported tool requires no training to use
and hence is potentially scalable.
Inclusion of clinical override
The screening tool should complement the role of clinical
judgement in violence risk assessment by identifying patients for
whom detailed assessment may not be needed. Nevertheless, a
number of risk factors that this tool does not measure may have
clinical significance and more research is warranted to determine
their value. For example, associations have been found between
violence and non-adherence to medication [40], lack of insight
[41], and psychotic symptoms such as persecutory delusions and
command hallucinations [42]. In certain cases, clinicians may
consider such factors as highly relevant (e.g., if they were
associated with previous violence). Therefore, we have included
a clinical override option in our coding sheet (Figure 1).
Comparison with previous research
While several violence risk assessment instruments have been
developed for general psychiatric populations [43–45], no tools to
our knowledge have been designed as part of a stepped strategy for
individuals with a specific psychiatric diagnosis [10]. In relation to
the latter, as epidemiological investigations have shown that the
base rate of violence varies by diagnosis [46] and existing tools
may perform differently across diagnostic groups [10], general
screening approaches are likely to lose sensitivity and specificity.
Some evidence suggests that developing risk assessment tools for
more specific populations may improve predictive validity [47].
One such instrument is an actuarial tool designed to predict assault
in individuals diagnosed with psychotic disorders [48]. The
calibration study for this instrument, a two-year clinical trial
examining different models of community care in UK inner cities,
found that demographic information was helpful in risk prediction
[48,49]. However. unlike the screening tool developed in the
present study, this measure was designed to identify high risk
individuals and hence produced a higher rate of false negatives
(13% at 2 year follow-up compared with less than 1% in the
present study).
The current screening instrument’s success in screening out very
low risk patients may be attributed to two sources. First, the tool
was statistically developed so that it only includes risk factors that
account for variance independently, and the selected cut-off
maximises sensitivity and minimises the number of false negative
predictions. Second, each of the risk factors has been proposed to
lie on the causal pathway to violence. For example, increased
levels of testosterone may predispose male patients with schizo-
phrenia to aggression [50]. Further, there is evidence to suggest
Table 1. Descriptive characteristics of the calibration and cross-validation samples of a violence screening tool for individuals with
hospital discharge diagnoses of schizophrenia.
Sample
Domain Variable
Calibration
sample (n=6903)
Cross-validation
sample 1 (n=2301)
Cross-validation
sample 2 (n=2301)
Cross-validation
sample 3 (n=2301)
Adjusted HR
a
(95% CI)
Demographic factors Male sex, n (%) 4392 (63.6) 1480 (64.3) 1504 (65.4) 1515 (65.8) 3.3 (2.7–4.0)
Age at assessment
(in years), mean (SD)
28.9 (7.2) 28.9 (7.2) 29.2 (7.2) 29.2 (7.3) 1.9 (1.6–2.3)
Non-completion of
compulsory school,
n (%)
2005 (29.1) 660 (28.7) 679 (29.5) 692 (30.1) 1.4 (1.2–1.6)
Individual factors Previous criminal
conviction, n (%)
2806 (40.7) 899 (39.1) 974 (42.3) 978 (42.5) 3.3 (2.8–3.8)
Alcohol abuse
comorbidity, n (%)
1078 (15.6) 353 (15.3) 353 (15.3) 331 (14.4) 2.9 (2.5–3.4)
Drug (non-alcohol)
abuse comorbidity,
n (%)
1151 (16.7) 360 (15.6) 389 (16.9) 357 (15.5) 3.5 (3.1–4.0)
Familial factors Father convicted of
a violent offence,
n (%)
127 (1.8) 41 (1.8) 39 (1.7) 35 (1.5) 2.3 (1.7–3.2)
Mother convicted of
a violent offence,
n (%)
17 (0.2) 7 (0.3) 6 (0.3) 7 (0.3) 2.8 (1.4–5.3)
Father alcohol abuse
comorbidity, n (%)
539 (7.8) 188 (8.2) 163 (7.1) 147 (6.4) 1.4 (1.1–1.8)
Mother alcohol abuse
comorbidity, n (%)
179 (2.6) 56 (2.4) 60 (2.6) 68 (3.0) 1.8 (1.3–2.5)
Base rate of violent
conviction
b
n (%) 887 (12.9) 309 (13.4) 321 (14.0) 275 (12.0)
Note: HR=hazard ratio; CI=confidence interval; SD=standard deviation.
aAdjusted by age at assessment and sex using participants from the calibration sample.
bBetween January 1, 1973 and December 31, 2004.
doi:10.1371/journal.pone.0031727.t001
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violence screening tool for individuals with hospital discharge diagnoses of schizophrenia.
Length of follow-up Risk score True positives True negatives False positives False negatives Sensitivity Specificity
1y e a r( n=6645) 0 47 0 6598 0 1.00 0.00
1 46 604 5994 1 0.98 0.09
2* 41 2353 4245 6 0.87 0.36
3 26 4493 2105 21 0.55 0.68
4 14 5750 848 33 0.30 0.87
5 3 6380 218 44 0.06 0.97
2 years (n=6407) 0 93 0 6314 0 1.00 0.00
1 90 573 5741 3 0.97 0.09
2* 83 2245 4069 10 0.89 0.36
3 58 4300 2014 35 0.62 0.68
4 29 5505 809 64 0.31 0.87
5 9 6104 210 84 0.10 0.97
5 years (n=5666) 0 224 0 5442 0 1.00 0.00
1 216 475 4967 8 0.96 0.09
2* 202 1961 3481 22 0.90 0.36
3 138 3762 1680 86 0.62 0.69
4 64 4776 666 160 0.29 0.88
5 15 5261 181 209 0.07 0.97
Note: Participants from the calibration sample were excluded if they were not at risk for 1, 2, or 5 years (respectively).
*Cut-off score.
doi:10.1371/journal.pone.0031727.t002
Table 3. Comparison of outcome measures calculated during calibration and cross-validation of a violence screening tool for
individuals with hospital discharge diagnoses of schizophrenia.
Outcome measure
Length of follow-up Sample NPV (95% CI) PPV (95% CI) DOR (95% CI) AUC (95% CI)
1 year Calibration sample (n=6645) 0.99 (0.99–1.00) 0.01 (0.01–0.02) 3.79 (1.65–8.72) 0.67 (0.59–0.74)
Cross-validation sample 1
(n=2205)
0.99 (0.99–1.00) 0.01 (0.01–0.02) 5.16 (1.33–20.04) 0.74 (0.62–0.85)
Cross-validation sample 2
(n=2205)
0.99 (0.99–1.00) 0.01 (0.01–0.02) 2.07 (0.73–5.93) 0.66 (0.54–0.78)
Cross-validation sample 3
(n=2190)
0.99 (0.99–1.00) 0.01 (0.01–0.02) 5.14 (1.34–19.93) 0.62 (0.53–0.71)
2 years Calibration sample (n=6407) 0.99 (0.99–1.00) 0.02 (0.02–0.03) 4.58 (2.40–8.74) 0.69 (0.64–0.74)
Cross-validation sample 1
(n=2136)
0.99 (0.99–1.00) 0.02 (0.02–0.03) 17.89 (3.08–103.80) 0.75 (0.67–0.82)
Cross-validation sample 2
(n=2111)
0.99 (0.98–1.00) 0.02 (0.02–0.03) 2.56 (1.09–6.03) 0.67 (0.58–0.75)
Cross-validation sample 3
(n=2111)
0.99 (0.99–1.00) 0.02 (0.02–0.03) 3.12 (1.24–7.82) 0.65 (0.57–0.73)
5 years Calibration sample (n=5666) 0.99 (0.98–0.99) 0.06 (0.05–0.06) 5.17 (3.33–8.03) 0.69 (0.66–0.73)
Cross-validation sample 1
(n=1875)
0.99 (0.98–0.99) 0.06 (0.05–0.06) 4.10 (2.12–7.91) 0.68 (0.63–0.74)
Cross-validation sample 2
(n=1879)
0.98 (0.97–0.99) 0.05 (0.05–0.06) 3.08 (1.63–5.81) 0.68 (0.62–0.74)
Cross-validation sample 3
(n=1868)
0.98 (0.97–0.99) 0.05 (0.04–0.05) 2.21 (1.23–3.95) 0.66 (0.60–0.72)
Note: NPV=negative predictive value; PPV=positive predictive value; DOR=diagnostic odds ratio; AUC=area under the curve; CI=confidence interval. Participants
from the calibration and cross-validation samples were excluded if they were not at risk for 1, 2, or 5 years (respectively). All AUCs were significantly higher than chance.
Test statistics reported no significant differences between the effect estimates produced by the calibration and cross-validation samples. The instrument’s PPV increased
significantly over time in both the calibration and the cross-validation samples. Differences in DOR and AUC were non-significant despite evidence of non-overlapping
confidence intervals.
doi:10.1371/journal.pone.0031727.t003
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ferase (COMT) Val158Met polymorphism, which has recently
been put forth as an important neurobiological risk factor for
violence in schizophrenia [51], increases violence risk solely in
men [52]. Young age may increase violence risk, as aging reduces
testosterone levels in both sexes [53] and is associated with
Table 4. A comparison of the positive and negative predictive values for a violence screening tool for individuals with hospital
discharge diagnoses of schizophrenia across different base rates of violent conviction.
Base rate of violent conviction
Length of follow-up Outcome measure 0% 2% 4% 6% 8% 10%
1y e a r( n=6645) NPV (95% CI) 0.99 (0.99–1.00) 0.99 (0.99–1.00) 0.99 (0.98–0.99) 0.98 (0.97–0.98) 0.97 (0.97–0.98) 0.96 (0.96–0.97)
PPV (95% CI) 0.01 (0.00–0.01) 0.03 (0.01–0.07) 0.05 (0.03–0.08) 0.08 (0.06–0.11) 0.11 (0.08–0.13) 0.13 (0.11–0.15)
2 years (n=6407) NPV (95% CI) 0.99 (0.99–1.00) 0.99 (0.99–1.00) 0.99 (0.98–0.99) 0.98 (0.97–0.98) 0.97 (0.97–0.98) 0.97 (0.96–0.97)
PPV (95% CI) 0.01 (0.00–0.01) 0.03 (0.01–0.07) 0.05 (0.03–0.09) 0.08 (0.06–0.11) 0.11 (0.09–0.13) 0.13 (0.11–0.16)
5 years (n=5666) NPV (95% CI) 0.99 (0.99–1.00) 0.99 (0.99–1.00) 0.99 (0.98–0.99) 0.98 (0.97–0.98) 0.98 (0.97–0.98) 0.97 (0.96–0.97)
PPV (95% CI) 0.01 (0.00–0.01) 0.03 (0.01–0.07) 0.06 (0.04–0.09) 0.08 (0.06–0.11) 0.11 (0.09–0.13) 0.14 (0.11–0.16)
Note: PPV=positive predictive value; NPV=negative predictive value; CI=confidence interval. Values based on participants from the calibration sample. Participants
were excluded if they were not at risk for 1, 2, or 5 years (respectively).
doi:10.1371/journal.pone.0031727.t004
Figure 1. Proposed violence screening tool for individuals with schizophrenia.
doi:10.1371/journal.pone.0031727.g001
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of alcohol or drug abuse may be markers of violence risk because
they may reflect an antisocial lifestyle with an increased likelihood
of having antisocial peers, procriminal attitudes, unemployment,
exposure to destabilizers, and lack of adherence to treatment [55].
In addition, alcohol or drug use at the time of the violent offence
may have acted as a disinhibitor. Despite this, this study was not
designed to test causal mechanisms, and the screening tool clearly
does not represent a causal model of violence risk.
To our knowledge, the simple screen presented in this report is
the first risk assessment tool to have been designed to predict the
likelihood of community violence in a specific diagnostic group, to
have been constructed for use in identifying low as opposed to high
risk patients, and to have been developed using a register-based
sample of several thousand individuals, allowing for the calculation
of more precise effect estimates than previous work. The
calibration and cross-validation samples for the screening tool
were several orders of magnitude larger than development studies
for currently available actuarial risk assessment tools [56,57].
Implications
When used as part of a stepped approach to violence risk
assessment, screen out tools can potentially save psychiatric
services considerable resources although future research will have
to test this in practice. Recent UK and US surveys have found that
instruments which employ structured clinical judgement, where
clinicians use empirically-based risk and protective factors to guide
their predictions as to whether an individual will be violent, are
amongst the most commonly used tools [58,59]. With the time
involved in administering such tools (familiarising oneself with the
patient’s case, collecting information from multiple sources to
score items, conducting interviews, scoring the tool, and making a
clinical judgement regarding risk level) and the costs involved
(attending training sessions, purchasing tool manuals, and paying
for each coding sheet), violence risk assessment, as often currently
conducted, costs mental health services significant amounts of time
and money. In a recent survey of forensic mental health
professionals, Viljoen and colleagues [33] reported that using a
structured tool to conduct a risk assessment takes an average of
15 hours and costs service providers an average of $100 USD per
hour to complete. Therefore, screening tools that require little
training, that are based on items scored using routinely available
information, and can reduce caseload are potentially attractive. It
should be noted, however, that patients with schizophrenia who
are screened out will continue to need mental health resources to
treat their illness. Therefore, while screening tools such as that
developed in the present study may be of use in identifying patients
who do not need management of their violence risk, they should
not be used to ration treatment.
The results of the present investigation also suggest that
reporting a single effect size does not provide an adequate picture
of a risk assessment tool’s predictive validity. Global effect
estimates such as the AUC and the DOR do not measure the
relative utility of an instrument in making ‘‘rule in’’ decisions (i.e.,
identifying who will go on to violently offend) versus ‘‘rule out’’
decisions (i.e., identifying who will not go on to violently offend).
Had only AUCs or DORs have been reported for the simple tool
in this study, different conclusions could have emerged about how
the tool performed. AUCs below 0.70 may have been interpreted
as evidence that the screening tool lacked any utility as a violence
risk assessment instrument [60], whereas DORs above 5 may have
been interpreted as evidence that the screen performed well in
identifying both high and low risk patients [24]. It was only by
examining the PPVs and NPVs of the tool that a clear picture
emerged of how the instrument performed. Future studies
investigating the predictive validity of forensic risk assessment
tools should consider reporting a global effect estimate (e.g., AUC
or DOR) as well as at least one ‘‘rule in’’ and ‘‘rule out’’ effect size
(e.g., PPV and NPV, respectively).
Limitations
There are several limitations of the present investigation. First,
we relied on hospital data to identify schizophrenia cases.
Therefore, our screen is applicable only to patients discharged
from hospital, although other research has estimated that a
minority of individuals in Sweden who have schizophrenia would
not have been hospitalised over a 30-year period [61]. By
excluding individuals with only a single discharge diagnosis, we
will not have included all hospitalised individuals with schizo-
phrenia. However, by including only those individuals with two
diagnoses of schizophrenia, our sample had the advantage of
diagnostic specificity [17]. That is, participants were less likely to
have other diagnoses such as drug-induced psychosis or bipolar
disorder. Related work has shown similar base rates of violence in
those with one or more diagnoses of schizophrenia [1], so it is
possible that the screen is generalisable to all hospitalised patients
with the disorder. Further, as the prevalence [62,63] and
disability-adjusted life years [64] of individuals with schizophrenia
and the rate of violent crime [65] in Sweden are similar to Western
Europe and other regions, our findings may have some
generalisability to other nations.
A second limitation was that the positive predictive values
produced by the screening instrument were low. That is, patients
who were not screened out by the simple tool were rarely
convicted of violent crimes (i.e., false positives). This is likely a
consequence of the low base rate of violence in individuals with
schizophrenia and supports the assumption of the stepped
approach that individuals who score highly on our tool should
not be considered as moderate or high risk of violence, but rather
as warranting a more comprehensive risk assessment. In this
context, false positive predictions are not problematic, as a low-risk
patient who is not screened out would receive what is currently
treatment-as-usual: an in-depth clinically-based risk assessment.
These findings highlight the challenge of identifying individuals at
high risk of violence in populations with low base rates [66], and
also the need for more research on improving structured risk
instruments, possibly using other variables that we were unable to
test using register-based measures.
A third limitation of the present investigation was that evidence of
minimal shrinkage effects may have been due to our calibration and
cross-validation samples having been selected from the same
population, which had a low overall base rate of violence. Also,
variables were coded the same way for both the construction and
replication samples. Future work will have to test the predictive
validity ofthe screening tool in different settings(e.g., non-hospitalised
patients) and outcomes (e.g., violence not reported to the police).
A fourth limitation is that the screening tool does not
discriminate in young men, who would all screen positive.
Therefore, it may be that the screen provides the most clinical
utility in women and older men. Future research could consider
more discriminating tools in young men.
Future Directions
Before the stepped approach to risk assessment could be
considered in clinical practice, it would need further validation,
including clinical studies in other countries to assess the
generalisability of the present study’s findings. These studies
should be prospective and include both economic analyses (i.e.,
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after) and qualitative analyses to explore clinicians’ perceptions of
this novel approach.
In addition, as clinicians may be interested in tools that predict
more than one adverse outcome [67], future studies may wish to
investigate the utility of the screening instrument in the prediction
of other adverse outcomes such as suicide. In support, a systematic
review has found male sex, criminal history, young age, and
substance abuse to be significant risk factors for suicide in
schizophrenia [68–70].
To what extent the five factors included on the screening tool
are specific to schizophrenia also needs further investigation. For
two factors, it is unlikely: the age cut-off in this instrument (32
years) is older than the median age of offending in general
populations [71], and rates of substance abuse comorbidity are
substantially higher in patients with schizophrenia than general
population samples [72].
Conclusion
The aim of the present study was to develop a simple instrument
to identify those individuals diagnosed with schizophrenia who are
at very low risk of violence after hospital discharge. We aimed to
design a tool that used routinely available information and was
straightforward to administer. With reasonably high rates of
accuracy, the use of five items, no complicated weighting
algorithm, and an easy to interpret classification system (screen
out vs. continue risk assessment), our findings suggest that using a
stepped strategy in which very low risk patients are screened out
prior to in-depth risk assessment may assist in improving the
quality of violence risk assessment in schizophrenia.
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